Neurotech Device Sector Shows Growth, But Challenges Await
This article was originally published in The Gray Sheet
Participants at the recent Neurotech Investing and Partnering Conference are generally optimistic about the commercial potential for neurotechnology.
You may also be interested in...
Neurological devices panel votes in favor of device intended to reduce epileptic seizures despite lingering questions about the trial results.
Public Company Edition: Cancer-focused Adlai Nortye launched a concurrent initial public offering and private placement, while four other drug developers announced or completed SPAC mergers. Also, Sobi grossed $540m in a rights issue and Immunovant followed early data with a $450m FOPO.
The company anticipates potential sales in excess of $1bn for the late-onset Pompe disease drug by the end of the decade.